Adjuvant chemotherapy after surgery for pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new chemotherapy combination after surgery for pancreatic cancer to see if it helps prevent the cancer from coming back. It compares the new treatment to a standard one.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had surgery to remove your pancreatic cancer and are recovering well.
- You are generally able to do daily activities (ECOG score 0 or 1).
- You are expected to live at least 6 months.
- You can start treatment within 3 to 12 weeks after surgery.
- Your blood counts and organ function are within acceptable ranges.
- You have not had chemotherapy or radiation before surgery for this cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares adding radiation to chemotherapy versus chemotherapy alone after surgery for pancreatic cancer. It is for people whose cancer had certain high-risk features found during surgery, and who have not yet started additional treatment.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This study compares two different chemotherapy combinations after surgery for pancreatic cancer. The goal is to see which is better at preventing the cancer from coming back. You would receive either liposomal irinotecan with oxaliplatin and S-1, or gemcitabine with capecitabine.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
This trial tests whether combining radiation therapy with chemotherapy (called the GX regimen) after pancreatic cancer surgery helps prevent cancer from returning in patients with high-risk features. The study aims to see if this combination treatment improves outcomes compared to standard care.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.